CM
Therapeutic Areas
Bicara Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| BCA101 | Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) | Phase 1b/2 |
Leadership Team at Bicara Therapeutics
F(
Fortunato (Fred) C. O. (Chuck) Olson
Chief Scientific Officer
DJ
David J. Donabedian
Chief Technology Officer
MJ
Mark J. Charette
Chief Business Officer
DS
David S. Grayzel
Chief Medical Officer
J(
James (Jim) P. Boylan
Chief Financial Officer